Preclinical dose response study shows NR2E3 can attenuate retinal degeneration in the retinitis pigmentosa mouse model RhoP23H+/−Shannon M. McNamee, Neena B. Haider, Maiya Whalen et al.|Gene Therapy|2024Cited by 10
Evaluating therapeutic potential of NR2E3 doses in the rd7 mouse model of retinal degenerationShannon M. McNamee, Neena B. Haider, Monica Akula et al.|Scientific Reports|2024Cited by 3
Preclinical biodistribution and toxicology assessment of an AAV5-based subretinal modifier gene therapy for retinitis pigmentosaArun K. Upadhyay, Rasappa Arumugham|Frontiers in Medicine|2025Cited by 0